VYNE Therapeutics Business Summary

VYNE Therapeutics Inc. (VYNE) is a clinical-stage biopharmaceutical company that primarily generates revenue through royalty-based licensing agreements, most notably from its partnership with LEO Pharma A/S for the Finacea foam product. As of March 2026, the company is undergoing a transformative strategic shift following a December 2025 merger agreement with Yarrow Bioscience, Inc., which is expected to close in Q2 2026. This transaction pivots VYNE’s focus from its legacy BET inhibitor platform (including VYN202) toward Yarrow’s lead clinical candidate, YB-101, a monoclonal antibody targeting Graves’ disease and thyroid eye disease. The company operates within the highly competitive immuno-inflammatory and rare disease sectors, contending with established players such as Arcutis Biotherapeutics, Mayne Pharma, and Bausch Health. Relative to these competitors, VYNE currently occupies a micro-cap niche, seeking to transition from a royalty-dependent entity into a specialized immunology leader through its post-merger pipeline. VYNE’s leadership is headed by President and CEO David Domzalski, who previously served as CEO of Foamix Pharmaceuticals and held senior executive roles at LEO Pharma and Warner Chilcott. The executive team includes Dr. Iain Stuart as Chief Scientific Officer, Mutya Harsch as General Counsel, and Tyler Zeronda as Chief Financial Officer, all of whom bring extensive experience from legacy organizations like Foamix and Menlo Therapeutics. The Board of Directors is bolstered by industry veterans such as Lead Independent Director Patrick LePore, former Chairman of Par Pharmaceutical, and Sharon Barbari, former CFO of Cytokinetics and Gilead Sciences. The company’s institutional backing includes notable investors such as Access Industries, Adage Capital Partners, and DAFNA Capital Management, reflecting a pedigree of support from specialized life sciences funds during its transition toward the Yarrow Bioscience integration.